Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rechallenge

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Rechallenge. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-002891-15 Sponsor Protocol Number: 1506 Start Date*: 2012-09-18
    Sponsor Name:VU University Medical Center
    Full Title: Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma.
    Medical condition: Metastatic renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003644-37 Sponsor Protocol Number: HE6B/16 Start Date*: 2017-08-01
    Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG)
    Full Title: Single-arm phase II study of panitumumab rechallenge in combination with oxaliplatin or irinotecan-based chemotherapy in patients with RAS wild type advanced colorectal cancer.
    Medical condition: RAS wild type advanced colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) CY (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001430-19 Sponsor Protocol Number: ET21-084 Start Date*: 2021-07-08
    Sponsor Name: Centre Léon Berard
    Full Title: GIST-TEN: Randomized, prospective, multicentre, open label phase II study evaluating the interest of imatinib (Glivec) treatment maintenance or interruption after at least 10 years of treatment in ...
    Medical condition: locally advanced or metastatic Gastrointestinal Stromal Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018557-35 Sponsor Protocol Number: 2010-3 Start Date*: 2010-11-08
    Sponsor Name:University Medical Center Groningen
    Full Title: Desensitisation of ulcerative colitis patients intolerant for mesalazine treatment.
    Medical condition: Ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004690-14 Sponsor Protocol Number: NA Start Date*: 2021-01-12
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026311 Malignant neoplasm of ovary and other uterine adnexa LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061535 Ovarian neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000473-23 Sponsor Protocol Number: RETRY Start Date*: 2012-05-29
    Sponsor Name:GIOM - Gruppo Italiano Oncologia Nefrologica
    Full Title: PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER
    Medical condition: Metastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009251 Clear cell carcinoma of the kidney LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005774-37 Sponsor Protocol Number: GETNE-2016-01 Start Date*: 2016-04-29
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos. SECRETARÍA TÉCNICA GETNE (GETNE)
    Full Title: Phase II study to evaluate efficacy of rechallenge with Sunitinib in Patients with Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic who previously ...
    Medical condition: Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004635-30 Sponsor Protocol Number: UCL-ONCO-06-004 Start Date*: 2008-11-20
    Sponsor Name:CENTRE DU CANCER - CLINIQUES UNIVERSITAIRES SAINT-LUC
    Full Title: A randomized multicentric phase II study of prolonged adjuvant Temozolomide or "stop and go" in glioblastoma patients : the PATSGO study.
    Medical condition: It is an open-label, randomised multicentric phase II study of prolonged adjuvant Temozolomide versus "stop and go" in glioblastoma patients. This study will include a total of 70 patients. The st...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003275-30 Sponsor Protocol Number: 011-IRCC-10IIS-15 Start Date*: Information not available in EudraCT
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: Open-label, phase ii study of trastuzumab emtansine in patients with HER2-positive metastatic colorectal cancer progressing after trastuzumab and lapatinib: (HER2 Amplification for Colo-rectaL canc...
    Medical condition: metatastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001172 Adenocarcinoma of colon stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001126-15 Sponsor Protocol Number: CRICKET Start Date*: 2014-10-03
    Sponsor Name:G.O.N.O. (Gruppo Oncologico Nord Ovest)
    Full Title: A phase II single-arm study of cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing...
    Medical condition: metastatic colonrectal cancer KRAS, NRAS and BRAF wild type.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004593-56 Sponsor Protocol Number: CAVE-2 Start Date*: 2022-05-19
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients
    Medical condition: Pre-treated RAS/BRAF wild type metastatic colorectal cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003787-21 Sponsor Protocol Number: FIRE-4 Start Date*: 2015-03-11
    Sponsor Name:Klinikum der Ludwig-Maximilians-Univ. Münch , Klinikum Großhadern (vertreten durch die kaufmännische Direktion)
    Full Title: Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximab
    Medical condition: Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum (metastatic colorectal cancer), primarily non-resectable or with surgery refused by the patient
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002597-12 Sponsor Protocol Number: 013-IRCC-10IIS-16 Start Date*: 2017-03-09
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: A PHASE II TRIAL OF RECHALLENGE WITH PANITUMUMAB DRIVEN BY RAS CLONAL-MEDIATED DYNAMIC OF RESISTANCE. THE CHRONOS TRIAL.
    Medical condition: METASTATIC COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001172 Adenocarcinoma of colon stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006871-60 Sponsor Protocol Number: DIRECTOR Start Date*: 2009-06-23
    Sponsor Name:University Hospital Heidelberg, Ruprechts-Karl-University Heidelberg
    Full Title: Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma
    Medical condition: progressive or recurrent glioblastoma after first surgery for glioblastoma and after completion of radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001379-21 Sponsor Protocol Number: VX15-770-126 Start Date*: 2017-08-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Init...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002781-48 Sponsor Protocol Number: MedOPP068 Start Date*: 2019-02-08
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN H...
    Medical condition: Hormone receptor-positive/HER2-negative Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004827-29 Sponsor Protocol Number: VX14-661-110 Start Date*: 2015-09-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, ...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) AT (Completed) FR (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001298-17 Sponsor Protocol Number: 362/11 Start Date*: 2012-04-05
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Phase II study on ET-743 in BRCA1 and BRCA2 mutation carrie and BRCAness phenotype advanced ovarian cancer patients.
    Medical condition: advaced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000004-33 Sponsor Protocol Number: IPR/18 Start Date*: 2008-10-13
    Sponsor Name:MOLMED
    Full Title: NGR012: A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer
    Medical condition: Patients affected by advanced or metastatic ovarian cancer previously treated with platinum regimens (cis or carboplatin) plus paclitaxel
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002834-35 Sponsor Protocol Number: PARERE Start Date*: 2020-09-24
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients.
    Medical condition: RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 12:03:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA